ストックスクリーナーアプリを入手
53.57
3.20%
1.66
アフターアワーズ：
53.57
前日終値:
$51.91
開ける：
$51.33
24時間の取引高:
3.25M
Relative Volume:
1.36
時価総額：
$10.29B
収益：
$2.95B
当期純損益:
$523.88M
株価収益率:
19.91
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
-1.67%
1か月 パフォーマンス:
-1.09%
6か月 パフォーマンス:
-15.89%
1年 パフォーマンス:
-18.70%
1日の値動き範囲:
$51.00
$53.62
1週間の範囲:
$51.00
$56.80
52週間の値動き範囲:
$51.00
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
BMRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.57 | 9.97B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-08 | 開始されました | H.C. Wainwright | Neutral |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-24 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 開始されました | Evercore ISI | Outperform |
| 2023-11-15 | 開始されました | Wells Fargo | Overweight |
| 2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-18 | 開始されました | UBS | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 開始されました | Citigroup | Neutral |
| 2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-09 | アップグレード | Stifel | Hold → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-04 | 再開されました | Guggenheim | Buy |
| 2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | ダウングレード | Stifel | Buy → Hold |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 繰り返されました | Citigroup | Buy |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-04-09 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 繰り返されました | Stifel | Buy |
| 2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsJuly 2025 Outlook & Free Technical Pattern Based Buy Signals - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecastsEarnings Risk Report & Verified Trade Idea Suggestions - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
What is William Blair's Estimate for BMRN Q4 Earnings? - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 14,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap by valuation metricsJuly 2025 Drop Watch & Free Weekly Watchlist of Top Performers - newser.com
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetOptions Play & Weekly Return Optimization Plans - newser.com
Why BioMarin Pharmaceutical Inc. stock is in analyst buy zoneWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) - MSN
How to monitor BioMarin Pharmaceutical Inc. with trend dashboards2025 Valuation Update & High Yield Stock Recommendations - newser.com
10 Best Beaten Down Growth Stocks to Buy According to Analysts - Insider Monkey
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Cantor Fitzgerald Has Negative View of BMRN FY2025 Earnings - MarketBeat
How currency fluctuations impact BioMarin Pharmaceutical Inc. stock2025 Technical Overview & Safe Swing Trade Setups - newser.com
How to read the order book for BioMarin Pharmaceutical Inc.Market Activity Report & Daily Profit Focused Stock Screening - newser.com
Sentiment analysis tools applied to BioMarin Pharmaceutical Inc.Global Markets & AI Enhanced Trading Alerts - newser.com
BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 - Insider Monkey
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
BioMarin Pharmaceutical Inc. Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD By Investing.com - Investing.com South Africa
After a futile battle, Biomarin will sell the bleeding disorder drug Roctavian - medwatch.com
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD - Investing.com
Cantor Fitzgerald Issues Negative Forecast for BMRN Earnings - MarketBeat
BioMarin Pharma plans to divest struggling gene therapy - MSN
Results: BioMarin Pharmaceutical Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - 富途牛牛
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Wedbush - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company - MarketBeat
Stifel Nicolaus Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $73.00 - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $80.00 at Barclays - MarketBeat
BioMarin (NASDAQ: BMRN) PALYNZIQ sBLA gets FDA Priority Review to expand to ages 12–17 - Stock Titan
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Morgan Stanley Lowers BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $98.00 - MarketBeat
Teacher Retirement System of Texas Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Asset Management One Co. Ltd. Has $4.84 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth - TipRanks
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):